Palvella Therapeutics Inc(PVLA) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Nov 3 at 4:00 PM ET (Korea 11/4 06:00)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -4.84 | Insider Own | 36.41% | Shs Outstand | 14.4M | Perf Week | 15.06% |
| Market Cap | 2.20B | Forward P/E | - | EPS next Y | -26.08% | Insider Trans | -1.52% | Shs Float | 9.2M | Perf Month | 15.72% |
| Enterprise Value | 1.98B | PEG | - | EPS next Q | -1.72 | Inst Own | 89.35% | Short Float | 26.28% | Perf Quarter | -1.28% |
| Income | -0.06B | P/S | - | EPS this Y | -77.18% | Inst Trans | 13.8% | Short Ratio | 11.15 | Perf Half Y | 18.12% |
| Sales | 0.00B | P/B | 10.15 | EPS next 5Y | -21.81% | ROA | -37.7% | Short Interest | 2.41M | Perf YTD | 46.11% |
| Book/sh | 15.06 | P/C | 8.79 | EPS past 3/5Y | 53.08% 41.62% | ROE | -46.63% | 52W High | -5.24% ($161.38) | Perf Year | 99.02% |
| Cash/sh | 17.39 | P/FCF | - | Sales past 3/5Y | - | ROIC | -25.78% | 52W Low | 113.74% ($71.55) | Perf 3Y | 633.55% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 61.66% | Gross Margin | - | Volatility(W/M) | 7.28% 5.92% | Perf 5Y | -59.15% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 7.76 | Perf 10Y | 33.68% |
| Dividend Ex-Date | - | Quick Ratio | 21.18 | EPS Q/Q | -77.78% | Profit Margin | - | RSI (14) | 64.35 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 21.18 | Sales Q/Q | - | SMA20 | 14.88% ($133.12) | Beta | -0.24 | Target Price | $227.88 |
| Payout | - | Debt/Eq | 0.1 | Earnings | 2026/11/5 | SMA50 | 7.93% ($141.69) | Rel Volume | 1.57 | Prev Close | $146.33 |
| Employees | 29 | LT Debt/Eq | 0.1 | EPS/Sales Surpr. | -29.55% - | SMA200 | 20.03% ($127.41) | Avg Volume(3M) | 0.22M | Price | $152.93 |
| IPO | 2015/1/2 | Option/Short | Yes/Yes | Trades | 6670 | Volume | 339,590 | Change | 4.51% |
🧬 A US clinical-stage biotech company developing treatments for rare skin diseases. It develops topical therapies targeting rare skin and connective tissue disorders with significant unmet medical needs, and has a lead candidate in late-stage clinical development. As a growth-stage biotech aimed at the underserved rare skin disease space, the stock is driven by business progress and market sentiment.
Over the past 1 year, on the higher side
5% below its 1-year high.
Traded more than usual. That is 157% of its average volume.
Next earnings report: November 5
1 days to go.
PVLA has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -77.2% this year.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -59.1%. The S&P 500 did +62% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Short interest is a burden
26.3% of the float is sold short.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #90 of 597 in the industry
Based on market cap of $2B.
AUPH#88 Aurinia Pharmaceuticals Inc $2B PER 7.2 
VERA#89 Vera Therapeutics Inc $2B PER - PVLA#90 Palvella Therapeutics Inc $2B PER - 
RXRX#91 Recursion Pharmaceuticals Inc $2B PER - 
HRMY#92 Harmony Biosciences Holdings Inc $2B PER 12.0 
FAQ
What kind of company is PVLA?
PVLA belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of PVLA?
The market cap of PVLA is approximately $2.2B, ranking 1,972 within its sector.
What is the 52-week high and low for PVLA?
PVLA has recorded a 52-week high of $161.38 and a low of $71.55.
